CLINICAL_TRIALS trial_result · 2010-12-15

Clinical Trial Update: Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED) [Phase 2]

Merck completed a Phase 2 study (MK-5757-005) evaluating cognitive impairment in men with schizophrenia; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2010-12-15